Publications

Sonoshita M., Scopton A.P., Ung P.M.U., Murray M.A., Silber L., Maldonado A.Y., Real A., Schlessinger A., Cagan R.L., Dar A.C. A Whole Animal Platform to Advance A Clinical Kinase Inhibitor Into New Disease Space. Nature Chemical Biology. Jan 22, 2018. PMID 29355849.

Dhawan, N.S., Scopton, A.P., Dar, A.C. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signaling. Nature. 2016. PMID: 27556948.

Dar AC. A pickup in pseudokinase activity. Biochem Soc Trans. 2013. Aug;41(4).

Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 2012 Jun; 486(7401).

Dar AC, Shokat KM. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annual review of biochemistry 2011 Jun; 80.

Brennan DF, Dar AC, Hertz NT, Chao WC, Burlingame AL, Shokat KM, Barford D. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 2011 Apr; 472(7343).

Dar AC, Lopez MS, Shokat KM. Small molecule recognition of c-Src via the Imatinib-binding conformation. Chemistry & biology 2008 Oct; 15(10).

Dar AC, Dever TE, Sicheri F. Higher-order substrate recognition of eIF2alpha by the RNA-dependent protein kinase PKR. Cell 2005 Sep; 122(6).